Welcome to our dedicated page for Eastman Kodak news (Ticker: KODK), a resource for investors and traders seeking the latest updates and insights on Eastman Kodak stock.
Eastman Kodak Company (NYSE: KODK) regularly issues news and updates that reflect its focus on commercial print, advanced materials & chemicals, and key financial and strategic developments. The company’s news flow includes quarterly and annual financial results, pension-related transactions, manufacturing initiatives and collaborations that draw on its long-standing strengths in coating, materials science and chemical processes.
Investors following KODK news will find detailed earnings releases for each quarter, where Kodak reports segment performance for Print, Advanced Materials & Chemicals (AM&C) and Brand, along with metrics such as gross profit, GAAP net income or loss, and Operational EBITDA. These releases often include management commentary on operational efficiency, growth initiatives in AM&C, trends in the print business and updates on liquidity and balance sheet structure.
Kodak’s news also covers capital structure and pension developments, including the termination of the Kodak Retirement Income Plan (KRIP), the use of annuity contracts and lump-sum payments to settle obligations, and the subsequent pension reversion that provided cash and investment assets to the company. Press releases describe how these proceeds are allocated between the new Kodak Cash Balance Plan and debt reduction, and how management views the impact on interest expense and financial flexibility.
Beyond financial and pension updates, Kodak publishes news about advanced materials and technology collaborations, such as its work with Ateios Systems on high-speed, solvent-free electrode production for lithium-ion batteries, and about brand and sponsorship activities, including support for the USA Bobsled/Skeleton team. Together, these items give readers insight into how Kodak applies its manufacturing and materials expertise across print, pharmaceuticals, energy storage and branded partnerships.
This news page aggregates such releases so readers can review Kodak’s latest financial disclosures, strategic initiatives and segment developments in one place.
Ateios Systems and Kodak (KODK) expanded the RaiCore™ electrode platform to LCO, LFP, and NMC cathodes and earned third-party PFAS-free verification. Independent testing found total organic fluorine below 20 ppm, well under the 100-ppm regulatory threshold. Ateios also launched 4th-generation RaiCore™ with >98% active material loading and pilot programs with leading OEMs.
NSF Energy Storage Engine grants and a non-FEOC supply chain supported validation and scale-up; samples and verification reports are available upon request.
Eastman Kodak Company (NYSE: KODK) reported Q4 and full‑year 2025 results showing revenue growth, improved gross profit and a stronger cash position. Consolidated Q4 revenue was $290M (+9% YoY) and FY revenue was $1.069B (+2% YoY).
Operational EBITDA rose to $22M in Q4 and $62M for FY 2025, while GAAP net loss was $108M in Q4 and $128M for the year. Year‑end cash was $337M, up $136M versus year‑end 2024.
Eastman Kodak (NYSE:KODK) will host its Fourth-Quarter and Full-Year 2025 earnings conference call on March 12, 2026 at 5:00pm EDT. Executive Chairman and CEO James Continenza and CFO David Bullwinkle will discuss financial results and answer investor questions.
A live webcast link is provided for public viewing and media and investor contacts are listed for follow-up.
Kodak (NYSE: KODK) expanded its pharmaceuticals portfolio on January 26, 2026, adding four regulated products: PBS 1X in low-endotoxin and RNase/DNase/Protease-free formulations and Water for Injection (WFI) in standard and RNase/DNase/Protease-free formulations. All four products are immediately available to U.S. research labs, biopharma developers, and CDMOs.
The products are manufactured in Kodak’s new cGMP-compliant pharmaceuticals facility in Rochester, NY, with lot-traceable quality, a multi-step water purification system, and sustainability features including energy-efficient lighting and water sterilization to reduce consumption and waste. Kodak said it is pursuing ISO 13485 certification and plans additional regulated pharmaceuticals in the future.
Kodak (NYSE: KODK) completed the pension reversion for $1.023 billion of excess KRIP assets on December 2, 2025, finalizing the KRIP transition. Approximately $767 million reverted to the company (including $609 million cash and $158 million non-cash), and Kodak used about $312 million of those proceeds to prepay term loans, reducing the outstanding term loan balance to $200 million. Kodak reports a net-positive cash position with a cash balance exceeding $300 million after excise tax. All KRIP retirement obligations were settled, and Kodak directed $251 million of investment assets plus $5 million cash to fully fund a new U.S. defined benefit plan, the Kodak Cash Balance Plan (KCBP), which will provide substantially the same benefits as KRIP’s cash balance feature.
Eastman Kodak (NYSE: KODK) reported Q3 2025 results on November 6, 2025: consolidated revenue of $269M (+3% vs. Q3 2024), gross profit $68M (+51%) and gross margin of 25% (vs. 17%). GAAP net income was $13M (down 28%) and Operational EBITDA was $29M (up $28M). Segment highlights: AM&C revenue $82M (+15%) and AM&C Operational EBITDA $16M. Quarter-end cash was $168M. Kodak completed a pension reversion with expected proceeds increasing from $500M to $600M, intends to use surplus to pay down debt, and says going concern disclosures have been fully resolved.
Eastman Kodak (KODK) will hold its Third-Quarter 2025 earnings conference call on Thursday, November 6, 2025 at 5:00 pm ET. Executive Chairman and CEO James Continenza and CFO David Bullwinkle will host the call to discuss Q3 2025 financial results with analysts and investors.
A live participant webcast will be available at the provided media-server link for those who wish to view the presentation and Q&A.
Contact details for investor and media inquiries are listed for Kurt Jaeckel (Worldwide Communications Director) and Anthony Redding (Shareholder Services).
Kodak (NYSE:KODK) announced on October 10, 2025 that its iconic yellow and red logo will appear on a new USA four-man bobsled as Kodak partners with USA Bobsled/Skeleton ahead of key races leading to 2026 international competition.
The sled was funded by entrepreneur and philanthropist Phil Saunders through Saunders Management. Kodak executives, athletes Frank Del Duca, Josh Williamson, Boone Niederhofer, Charlie Volker, coach Tuffy Latour, and analyst John Morgan unveiled the sled at Rochester’s Golisano Institute. The release referenced Kodak’s historical Olympic ties, including the 1956 "Tyler Sled."
Kodak (NYSE:KODK) and Ateios Systems have demonstrated a breakthrough in battery manufacturing technology with their RaiCure™ platform, achieving coating speeds of 80 meters per minute - nearly triple the industry standard. The solvent-free production process creates high-energy electrodes without using forever chemicals (PFAS).
The technology delivers up to 96% reduction in energy consumption and can produce over 500 MWh of high-energy electrodes annually on Kodak's pilot line, with full-scale production capacity exceeding 2 GWh per year. The partnership combines Ateios' electrode chemistry expertise with Kodak's manufacturing capabilities to serve the $196B global lithium-ion battery market.
Kodak (NYSE:KODK) reported challenging Q2 2025 financial results, with consolidated revenues of $263 million, down 1% from Q2 2024. The company posted a GAAP net loss of $26 million, a significant decline from a net income of $26 million in Q2 2024. Operational EBITDA decreased by 25% to $9 million.
The company's cash position weakened to $155 million, down from $201 million at the end of 2024. Notably, Kodak disclosed a going concern warning regarding its ability to meet preferred stock and debt obligations. The company plans to use proceeds from the Kodak Retirement Income Plan reversion to reduce debt, expected to complete by December 2025.
Despite challenges, Kodak reported progress in its Advanced Materials & Chemicals division, including FDA registration of its cGMP pharmaceutical manufacturing facility for regulated pharmaceutical products.